

# Mark P Connolly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3299011/publications.pdf>

Version: 2024-02-01

61  
papers

867  
citations

567281

15  
h-index

526287

27  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1032  
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 85, 217-228.	2.8	6
2	The public economic burden of sub-optimal type 2 diabetes control on tax payors in Sweden: Looking beyond health costs. <i>Diabetes, Obesity and Metabolism</i> , 2022, , .	4.4	2
3	Estimating the government public economic benefits attributed to investing in assisted reproductive technology: a South African case study. <i>Reproductive Biomedicine and Society Online</i> , 2021, 12, 14-21.	1.8	6
4	Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs. <i>Pharmacoeconomics</i> , 2021, 39, 257-269.	3.3	1
5	Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia. <i>Journal of Medical Economics</i> , 2021, 24, 123-130.	2.1	0
6	Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 127-136.	1.2	7
7	Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 127-136.	1.2	3
8	Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 346.	2.7	2
9	Cost-effectiveness Analysis of Hypoallergenic Milk Formulas for the Management of Cow's Milk Protein Allergy in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 14-25.	1.2	5
10	Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021, 8, 1-9.	2.7	8
11	Author Correction: Cost-effectiveness Analysis of Hypoallergenic Milk Formulas for the Management of Cow's Milk Protein Allergy in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 63.	1.2	0
12	Mobile Cardiac Outpatient Telemetry Patch vs Implantable Loop Recorder in Cryptogenic Stroke Patients in the US – Cost-Minimization Model. <i>Medical Devices: Evidence and Research</i> , 2021, Volume 14, 445-458.	0.8	6
13	Estimating the Fiscal Consequences of National Immunization Programs Using a "Government Perspective" Public Economic Framework. <i>Vaccines</i> , 2020, 8, 495.	4.4	5
14	The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden. <i>Journal of Medical Economics</i> , 2020, 23, 831-837.	2.1	5
15	&lt;p&gt;Costs Analysis of Fibrin Sealant for Prevention of Anastomotic Leakage in Lower Colorectal Surgery&lt;/p&gt;. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 5-11.	2.5	7
16	Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 603-612.	1.4	12
17	Sustainability of public finances: inclusion of unrelated medical cost only part of the story. <i>European Journal of Health Economics</i> , 2019, 20, 1281-1282.	2.8	0
18	Sustainability of public finances: inclusion of unrelated medical cost only part of the story. <i>European Journal of Health Economics</i> , 2019, 20, 1281.	2.8	0

#	ARTICLE	IF	CITATIONS
19	Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet Journal of Rare Diseases, 2019, 14, 220.	2.7	6
20	High burden and low awareness of toxoplasmosis in the United States. Postgraduate Medicine, 2019, 131, 103-108.	2.0	23
21	Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective. Journal of Bone Metabolism, 2019, 26, 253.	1.3	3
22	Fiscal Impact of Smoking Cessation in Thailand: A Government Perspective Cost-Benefit Analysis. Asia-Pacific Journal of Public Health, 2018, 30, 342-350.	1.0	2
23	Estimating the public economic consequences of introducing varenicline smoking cessation therapy in South Korea using a fiscal analytic framework. Journal of Medical Economics, 2018, 21, 571-576.	2.1	1
24	Cutaneous irritancy of an ibuprofen medicated plaster in healthy volunteers. Postgraduate Medicine, 2018, 130, 334-340.	2.0	0
25	A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. Clinical Pharmacology in Drug Development, 2018, 7, 684-691.	1.6	13
26	Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. Journal of Medical Economics, 2018, 21, 19-26.	2.1	14
27	Cutaneous irritancy of an ibuprofen medicated plaster in healthy volunteers. Postgraduate Medicine, 2018, 130, 19-23.	2.0	1
28	Efficacy and tolerability of a new ibuprofen 200mg plaster in patients with acute sports-related traumatic blunt soft tissue injury/contusion. Postgraduate Medicine, 2018, 130, 24-31.	2.0	10
29	Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany. Risk Management and Healthcare Policy, 2018, Volume 11, 77-82.	2.5	36
30	Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the Vizient Health Systems Data from 2011 to 2017. Pathogens and Global Health, 2018, 112, 428-437.	2.3	9
31	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2018, 21, 1133-1149.	0.3	94
32	Cost comparison of fibrin sealant versus tack screws for mesh fixation in laparoscopic repair of inguinal hernia. Hospital Practice (1995), 2018, 46, 233-237.	1.0	4
33	Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis. Pathogens and Global Health, 2017, 111, 31-44.	2.3	21
34	The Fiscal Consequences Attributed to Changes in Morbidity and Mortality Linked to Investments in Health Care: A Government Perspective Analytic Framework. Value in Health, 2017, 20, 273-277.	0.3	39
35	Systematic review and meta-analysis of secondary prophylaxis for prevention of HIV-related toxoplasmic encephalitis relapse using trimethoprim-sulfamethoxazole. Pathogens and Global Health, 2017, 111, 327-331.	2.3	17
36	Efficacy and safety assessment of acute sports-related traumatic soft tissue injuries using a new ibuprofen medicated plaster: results from a randomized controlled clinical trial. Physician and Sportsmedicine, 2017, 45, 418-425.	2.1	7

#	ARTICLE	IF	CITATIONS
37	A comparison of average wages with age-specific wages for assessing indirect productivity losses: analytic simplicity versus analytic precision. <i>European Journal of Health Economics</i> , 2017, 18, 697-701.	2.8	6
38	Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach. <i>PLoS ONE</i> , 2016, 11, e0160707.	2.5	10
39	Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. <i>Health Economics Review</i> , 2015, 5, 54.	2.0	20
40	Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. <i>Gastric Cancer</i> , 2015, 18, 627-634.	5.3	14
41	Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 357-362.	1.3	8
42	Is the gap between micro- and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies. <i>Journal of Market Access &amp; Health Policy</i> , 2014, 2, 23897.	1.5	15
43	Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. <i>Vaccine</i> , 2013, 31, 5430-5434.	3.8	15
44	The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. <i>Journal of Mental Health Policy and Economics</i> , 2013, 16, 27-33.	0.6	12
45	The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt. <i>Pharmacoeconomics</i> , 2012, 30, 681-695.	3.3	29
46	The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands. <i>Netherlands Journal of Medicine</i> , 2012, 70, 272-7.	0.5	4
47	Kiovig for primary immunodeficiency: Reduced infusion and decreased costs per infusion. <i>International Immunopharmacology</i> , 2011, 11, 1358-1361.	3.8	6
48	Cross-border reproductive care: market forces in action or market failure? An economic perspective. <i>Reproductive BioMedicine Online</i> , 2011, 23, 817-819.	2.4	11
49	The long-term fiscal impact of funding cuts to Danish public fertility clinics. <i>Reproductive BioMedicine Online</i> , 2011, 23, 830-837.	2.4	8
50	Economics of assisted reproduction: Access to fertility treatments and valuing live births in economic terms. <i>Human Fertility</i> , 2010, 13, 13-18.	1.7	17
51	The costs and consequences of assisted reproductive technology: an economic perspective. <i>Human Reproduction Update</i> , 2010, 16, 603-613.	10.8	142
52	Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis. <i>Digestion</i> , 2009, 80, 241-246.	2.3	21
53	The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment. <i>Human Reproduction</i> , 2009, 24, 2796-2800.	0.9	39
54	A cost per live birth comparison of HMG and rFSH randomized trials. <i>Reproductive BioMedicine Online</i> , 2008, 17, 756-763.	2.4	6

#	ARTICLE	IF	CITATIONS
55	Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. <i>Human Reproduction</i> , 2008, 24, 626-632.	0.9	48
56	Money in–babies out: assessing the long-term economic impact of IVF-conceived children. <i>Journal of Medical Ethics</i> , 2008, 34, 653-654.	1.8	2
57	Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: A lifetime tax perspective. <i>Scandinavian Journal of Public Health</i> , 2008, 36, 841-849.	2.3	15
58	An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. <i>Acta Gastro-Enterologica Belgica</i> , 2008, 71, 230-6.	1.0	2
59	Long-term economic benefits attributed to IVF-conceived children: a lifetime tax calculation. <i>American Journal of Managed Care</i> , 2008, 14, 598-604.	1.1	23
60	An economic evaluation of highly purified HMG and recombinant FSH based on a large randomized trial. <i>Reproductive BioMedicine Online</i> , 2007, 15, 500-506.	2.4	17
61	Evaluation of the Fiscal Costs and Consequences of Alzheimer’s Disease in Germany: Microsimulation of Patients’ and Caregivers’ Pathways. <i>Journal of Prevention of Alzheimer’s Disease</i> , The, 0, , .	2.7	2